Content of illicit cannabis extracts used to treat children with epilepsy revealed

The research, which commenced two years ago by the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics, not only sheds light on the composition of cannabis used in the community but also reveals the legal, bureaucratic, and cost issues faced by families who relied on the products, as well as demonstrating the barriers to accessing medicinal cannabis.

The study found that the main psychoactive ingredient in cannabis, tetrahydrocannabidiol (THC), and the closely related compound THCA, were present in most extracts, although the quantity was generally not enough to produce intoxicating effects. Just over half the extracts were associated with a seizure reduction of 75-100 percent, which reinforces observations from animal studies and case reports of anticonvulsant effects of THC and THCA. As well, 65 percent were associated with other beneficial effects like improved cognition (35 percent) and language skills (24 percent).

The findings are published today by Springer Nature in its leading journal, Scientific Reports.

Lead author and PhD candidate with the Lambert Initiative at the Brain and Mind Centre, Ms Anastasia Suraev, said just under half the families who used medicinal cannabis reduced their antiepileptic medication.

"Our findings highlight the huge unmet clinical need in the management of treatment-resistant epilepsy in childhood," said Miss Suraev, from the School of Psychology.

Corresponding author and academic director of the Lambert Initiative, Professor Iain McGregor, said: "Although the illicit extracts we analysed contained low doses of CBD, three in four were reported as 'effective', indicating the importance of researching the cannabis plant in its entirety for the treatment of epilepsy.

"And despite the overwhelming presence of generally low levels of THC, concentrations did not differ between samples perceived as 'effective' and 'ineffective'.

"Our research indicates there is a potential role for other cannabinoids, alone or in combination with conventional drugs, in treatment-resistant epilepsy -- and this warrants further investigation so we can hopefully develop safer and more effective medicines."